Azenta Authorizes $250 Million Share Repurchase Program

Azenta (Nasdaq: AZTA) announced a Board-approved $250 million share repurchase program.

Rhea-AI Summary

Azenta (Nasdaq: AZTA) announced a Board-approved $250 million share repurchase program.

The program began on Dec 9, 2025 and runs through Dec 31, 2028 unless earlier extended or terminated. Repurchases may be executed via open-market purchases, privately negotiated transactions, or other methods compliant with Rules 10b-18 and 10b5-1. The authorization is discretionary and does not obligate Azenta to buy any specific dollar amount or number of shares; repurchases can be commenced, suspended, modified, or discontinued at any time.

Management said the buyback is part of a capital allocation strategy alongside productivity, organic growth, and disciplined M&A to enhance long-term shareholder value.

Positive

• $250 million repurchase authorization
• Program active from Dec 9, 2025 to Dec 31, 2028
• Execution flexibility: open market and 10b5-1 methods

Negative

• Authorization is non‑binding; no guaranteed repurchases
• Repurchases may be suspended or discontinued at any time
• Uses up to $250 million of capital through 2028

Argus Dec 10 session

+2.53% close to close Open Argus

Details

News Market Reaction – AZTA

On Dec 10, the day this news came out, AZTA closed 2.53% above the previous close.

Data tracked by StockTitan Argus for the Dec 10 session.

Market Context

This announcement introduces a share repurchase program authorizing up to $250M in buybacks through ...

Analysis

This announcement introduces a share repurchase program authorizing up to $250M in buybacks through December 31, 2028. It follows FY2025 results showing revenue of $594M, adjusted EBITDA of $66M, and $546M in cash and securities, plus guidance for 3–5% organic growth in FY2026. Key factors to watch include the pace of actual repurchases, margin progress versus the planned ~300 bps expansion, and continued balance sheet strength.

Key Figures

Share repurchase authorization: $250M Q4 FY2025 revenue: $159M FY2025 revenue: $594M +5 more

Share repurchase authorization

$250M

Maximum common stock repurchases under new program

Q4 FY2025 revenue

$159M

Quarter ended September 30, 2025

FY2025 revenue

$594M

Full year fiscal 2025

FY2025 Adjusted EBITDA

$66M (11.2% margin)

Full year fiscal 2025

Cash & securities

$546M

As of FY2025 year-end

FY2026 organic growth

3–5%

Guidance for FY2026 organic revenue growth

Share price

$35.60

Pre-news price from market context

52-week range

$23.91–$55.64

52-week low and high from market context

Historical Context

5 past events · Latest: Nov 21

5 events

1. Nov 21

   Earnings results

   24h Move

   +16.3%

   Q4 and full-year FY2025 results with revenue growth and margin improvement.

2. Nov 12

   Conference call notice

   24h Move

   -2.9%

   Scheduled date and webcast details for upcoming Q4 and full-year call.

3. Nov 04

   Strategic partnership

   24h Move

   +1.2%

   Partnership with PRECEDE Foundation to support pancreatic cancer detection study.

4. Oct 15

   Investor day

   24h Move

   +4.7%

   Announcement of Investor Day with facility tour and executive presentations.

5. Aug 05

   Earnings results

   24h Move

   -17.0%

   Q3 FY2025 results with flat revenue, margin gains, and reiterated full-year guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

share repurchase program, rules 10b-18, 10b5-1

3 terms

share repurchase program financial

"has approved a share repurchase program under which the company may repurchase"

A share repurchase program is when a company buys back its own shares from the marketplace. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's prospects. For investors, it often suggests that the company believes its stock is undervalued or that it has extra cash to return to shareholders.

rules 10b-18 regulatory

"or by other methods compliant with Rules 10b-18 and 10b5-1 of the"

A set of U.S. Securities and Exchange Commission rules that gives companies a clear method for buying back their own shares without being accused of manipulating the market, provided they follow specific limits on timing, price, volume and the role of the broker. For investors, adherence signals that buybacks are structured and predictable, which can affect share supply, short-term price support and confidence in corporate use of cash — like rules for driving a company repurchase safely through traffic.

10b5-1 regulatory

"methods compliant with Rules 10b-18 and 10b5-1 of the Securities Exchange Act"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding common stock. The Repurchase Program is intended to enhance shareholder value and capitalize on undervaluation. Repurchases may be made from time to time through open market repurchases, privately negotiated transactions, or by other methods compliant with Rules 10b-18 and 10b5-1 of the Securities Exchange Act of 1934, subject to market and business conditions, applicable legal requirements, and other factors.

This authorization does not obligate Azenta to repurchase any specific dollar amount or number of shares, and repurchases may be commenced, suspended, modified, or discontinued at any time without prior notice. The Repurchase Program commenced on December 9, 2025, and continues until December 31, 2028, unless extended or terminated earlier by the Board.

"Our capital allocation strategy is grounded in four key levers — driving productivity and gross margin improvement, accelerating organic growth, pursuing strategic M&A with discipline, and returning capital to shareholders through share repurchases," said John Marotta, President and Chief Executive Officer. "The share repurchase authorization reflects our deliberate use of these levers to enhance long-term shareholder value while maintaining strategic flexibility to invest in growth."

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the share repurchase program and its potential benefits. Forward-looking statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could affect results include, among others, market conditions, business performance, stock price fluctuations, legal and regulatory requirements, and general economic conditions. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research, and advanced cell therapies for the industry's top pharmaceutical, biotech, academic, and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com

Maria Isabel Cuartas
Manager, Investor Relations
ir@azenta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-authorizes-250-million-share-repurchase-program-302638219.html

SOURCE Azenta

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Azenta's $250 million repurchase program mean for AZTA shareholders?

It authorizes up to $250 million to buy back shares, which can support EPS and return capital but is non‑binding and subject to market conditions.

When did Azenta's repurchase program for AZTA start and when does it end?

The program commenced on Dec 9, 2025 and continues until Dec 31, 2028 unless the Board extends or terminates it earlier.

How will Azenta execute share repurchases under the AZTA program?

Repurchases may occur via open market transactions, privately negotiated trades, or other methods compliant with Rules 10b-18 and 10b5-1.

Is Azenta required to repurchase the full $250 million under the AZTA authorization?

No. The authorization does not obligate Azenta to repurchase any specific dollar amount or number of shares.

Can Azenta pause or stop the AZTA buyback program?

Yes. Repurchases may be commenced, suspended, modified, or discontinued at any time based on business, market, or legal factors.